Remitoro
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, T-cell, Peripheral
Conditions
Lymphoma, T-cell, Peripheral, Lymphoma, T-cell, Cutaneous
Trial Timeline
May 24, 2021 → Mar 17, 2023
NCT ID
NCT05137847About Remitoro
Remitoro is a pre-clinical stage product being developed by Eisai for Lymphoma, T-cell, Peripheral. The current trial status is completed. This product is registered under clinical trial identifier NCT05137847. Target conditions include Lymphoma, T-cell, Peripheral, Lymphoma, T-cell, Cutaneous.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, T-cell, Peripheral were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05137847 | Pre-clinical | Completed |
Competing Products
20 competing products in Lymphoma, T-cell, Peripheral